Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

2022 ◽  
Author(s):  
Marc Ychou ◽  
Michel Rivoire ◽  
Simon Thezenas ◽  
Rosine Guimbaud ◽  
Francois Ghiringhelli ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trial ◽  
Targeted Therapy ◽  
Cancer Patients ◽  
Randomised Clinical Trial ◽  
Conversion Therapy ◽  
Ras Status ◽  
Colorectal Cancer Patients

The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment

2020 ◽  
Author(s):  
Serdar Arici ◽  
Jamshid Hamdard ◽  
Abdullah Sakin ◽  
Selma Sengiz Erhan ◽  
Muhammed Mustafa Atci ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Biological Agent ◽  
First Line ◽  
Ras Status ◽  
Colorectal Cancer Patients ◽  
Agent Treatment

Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy

2012 ◽  
Vol 38 (7) ◽  
pp. 617-623 ◽  
Author(s):  
Y.L.B. Klaver ◽  
L.H.J. Simkens ◽  
V.E.P.P. Lemmens ◽  
M. Koopman ◽  
S. Teerenstra ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapy ◽  
Peritoneal Carcinomatosis ◽  
Cancer Patients ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document